Form 4 for GYRE GYRE THERAPEUTICS, INC.
Accepted 2025-04-18 00:00:00 ET · period of report 2025-04-16 · accession 0001140361-25-014601 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-04-18 | 2025-04-16 | GYRE | Eastling Thomas Wilson | Dir | M - OptEx | $6.93 | +15.0K | 15.0K | New | +$104.0K |
| D | 2025-04-18 | 2025-04-16 | GYRE | Eastling Thomas Wilson | Dir | M - OptEx | $0.00 | -15.0K | 299.7K | -5% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-04-16 | M | A | 15,000 | $6.93 | 15,000 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-04-16 | M | D | 15,000 | $0.00 | 299,652 | D | $6.93 · — to 2033-10-31 | 15,000 Common Stock | (F1) These options are vested in full. |